方盛制药(603998.SH)通过药品GMP符合性检查

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) has received a GMP compliance inspection notice from the Hunan Provincial Drug Administration, indicating regulatory approval for specific production lines [1] Group 1: Company Announcement - The company announced the receipt of the GMP compliance inspection notice [1] - The inspection covers the production lines for Ezetimibe and Benidipine in the raw material drug workshop [1] - Specific areas inspected include the B and E zones for Ezetimibe and the A and E zones for Benidipine [1]